A Trial of NT-I7 in COVID-19 (SPESELPIS)

NCT04501796 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped Study was halted due to lack of patient population resulting in slow enrollment.

Conditions

COVID-19

Interventions

DRUG: Double-Blind NT-I7
DRUG: Double-Blind Placebo

Sponsor

NeoImmuneTech

Collaborators

[object Object]
[object Object]